Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PDA J Pharm Sci Technol ; 69(1): 96-107, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25691718

RESUMO

UNLABELLED: The primary container for parenterals is usually composed of glass. Given the recent industry-wide spike in glass-related problems, assays capable of detecting glass degradation before glass-related particles are visible in solution have practical significance. A rapid, high-throughput ion chromatography method coupled with molybdate reaction is described here for detection and quantitation of silicic acid (soluble form of silica) in complex samples. The method involves ion exchange separation of the silicate anion at high pH followed by a post-column derivatization step with sodium molybdate reagent. The resulting molybdo-silicate complex is detected with high sensitivity in the visible wavelength range at 410 nm and correlates to the level of soluble silica in solution. This assay is high-throughput and amenable for implementation during the early phase of product development. The assay provides a direct measurement to assess potential incompatibility between the formulation and its glass container. The Si levels measured by this method showed a direct correlation to the vial surface morphology changes as monitored by differential interference contrast microscopy. LAY ABSTRACT: Recently, the pharmaceutical industry has been faced with glass quality challenges that have resulted in many products being recalled from the market. Monitoring levels of soluble silica in solution is critical because silica is the primary component of glass containers used in the pharmaceutical industry. Given this recent industry-wide increase in glass-related problems, assays capable of detecting glass degradation before glass-related particles are visible in solution have practical significance. A rapid assay to detect the soluble form of silica is presented here. The method presented will enable earlier detection of a formulation and container incompatibility instead of waiting until glass-related particles are visible in solution.


Assuntos
Cromatografia por Troca Iônica/métodos , Embalagem de Medicamentos , Vidro/química , Ácido Silícico/química , Química Farmacêutica , Indústria Farmacêutica , Vidro/análise , Ensaios de Triagem em Larga Escala/métodos , Concentração de Íons de Hidrogênio , Molibdênio/análise , Molibdênio/química , Ácido Silícico/análise
2.
J Pharm Sci ; 104(2): 686-97, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25219372

RESUMO

Sorbitol crystallization-induced aggregation of mAbs in the frozen state was evaluated. The effect of protein aggregation resulting from sorbitol crystallization was measured as a function of formulation variables such as protein concentration and pH. Long-term studies were performed on both IgG1 and IgG2 mAbs over the protein concentration range of 0.1-120 mg/mL. Protein aggregation was measured by size-exclusion HPLC (SE-HPLC) and further characterized by capillary-electrophoresis SDS. Sorbitol crystallization was monitored and characterized by subambient differential scanning calorimetry and X-ray diffraction. Aggregation due to sorbitol crystallization is inversely proportional to both protein concentration and formulation pH. At high protein concentrations, sorbitol crystallization was suppressed, and minimal aggregation by SE-HPLC resulted, presumably because of self-stabilization of the mAbs. The glass transition temperature (Tg ') and fragility index measurements were made to assess the influence of molecular mobility on the crystallization of sorbitol. Tg ' increased with increasing protein concentration for both mAbs. The fragility index decreased with increasing protein concentration, suggesting that it is increasingly difficult for sorbitol to crystallize at high protein concentrations.


Assuntos
Anticorpos Monoclonais/química , Congelamento , Sorbitol/química , Animais , Anticorpos Monoclonais/metabolismo , Calorimetria/métodos , Química Farmacêutica , Cristalização , Imunoglobulina G/química , Imunoglobulina G/metabolismo , Agregados Proteicos/fisiologia , Sorbitol/metabolismo
3.
J Pharm Sci ; 103(4): 1104-14, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24496956

RESUMO

Visible particles were unexpectedly observed in a neutral-pH placebo formulation stored in glass vials but were not observed in the same formulation composition that contained protein. The particles were identified as silica gel (SiO2 ) and polysorbate 20, suggesting dissolution of the glass vial. Time course studies were performed to assess the effect of variables such as pH, excipients, storage temperature, and duration on particle formation. Data suggest that glass dissolution occurred during the storage in the liquid state, as shown by increased Si levels in solution. Upon freezing, the samples underwent freeze concentration and likely became supersaturated, which resulted in the appearance of visible silica particles upon thawing. The glass degradation described here is unique and differs from the more commonly reported delamination, defined by the presence of reflective, shard-like glass flakes in solution that are often termed lamellae. This case study underscores the importance of an early assessment (during formulation development) of potential incompatibility of the formulation with the primary container.


Assuntos
Vidro/química , Polissorbatos/química , Sílica Gel/química , Embalagem de Medicamentos , Excipientes/química , Congelamento , Concentração de Íons de Hidrogênio , Tamanho da Partícula , Solubilidade , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...